pregabalin and Cerebellar-Ataxia

pregabalin has been researched along with Cerebellar-Ataxia* in 2 studies

Trials

1 trial(s) available for pregabalin and Cerebellar-Ataxia

Article	Year
Single-blind, placebo-controlled pilot study of pregabalin for ataxia in cortical cerebellar atrophy. Acta neurologica Scandinavica, 2007, Volume: 116, Issue:4 To preliminarily compare the efficacy of pregabalin with that of placebo on the cerebellar signs caused by cortical cerebellar atrophy (CCA). A deficiency of gamma-aminobutyric acid (GABA) has been described in the cerebellum in CCA, and pregabalin has been shown to enhance GABA release in rat hippocampus.. Two consecutive patients with clinical diagnoses of CCA took part in the study. A placebo and pregabalin, 225 mg per day, were administered in a single-blind scheme during 15 day periods to every patient; cerebellar function was evaluated with the Scale for the Assessment and Rating of Ataxia (SARA) at the end of each period. A video recording of the SARA items performed by the first patient accompanies this article.. Total SARA scores of 19 and 15 were obtained for the patients after placebo administration. The SARA scores decreased to 11 and 8, respectively, with the administration of pregabalin; an important amelioration of the ataxia was also evident. Both patients preferred continuing treatment with pregabalin when the trial was over.. Pregabalin was superior to placebo in the improvement of the cerebellar signs caused by CCA. Further studies are needed to confirm the present results. Topics: Adult; Aged; Anticonvulsants; Atrophy; Cerebellar Ataxia; Female; Follow-Up Studies; gamma-Aminobutyric Acid; Humans; Male; Pilot Projects; Pregabalin; Recovery of Function; Single-Blind Method; Treatment Outcome	2007

Article

Year

Single-blind, placebo-controlled pilot study of pregabalin for ataxia in cortical cerebellar atrophy.

Acta neurologica Scandinavica, 2007, Volume: 116, Issue:4

To preliminarily compare the efficacy of pregabalin with that of placebo on the cerebellar signs caused by cortical cerebellar atrophy (CCA). A deficiency of gamma-aminobutyric acid (GABA) has been described in the cerebellum in CCA, and pregabalin has been shown to enhance GABA release in rat hippocampus.. Two consecutive patients with clinical diagnoses of CCA took part in the study. A placebo and pregabalin, 225 mg per day, were administered in a single-blind scheme during 15 day periods to every patient; cerebellar function was evaluated with the Scale for the Assessment and Rating of Ataxia (SARA) at the end of each period. A video recording of the SARA items performed by the first patient accompanies this article.. Total SARA scores of 19 and 15 were obtained for the patients after placebo administration. The SARA scores decreased to 11 and 8, respectively, with the administration of pregabalin; an important amelioration of the ataxia was also evident. Both patients preferred continuing treatment with pregabalin when the trial was over.. Pregabalin was superior to placebo in the improvement of the cerebellar signs caused by CCA. Further studies are needed to confirm the present results.

Topics: Adult; Aged; Anticonvulsants; Atrophy; Cerebellar Ataxia; Female; Follow-Up Studies; gamma-Aminobutyric Acid; Humans; Male; Pilot Projects; Pregabalin; Recovery of Function; Single-Blind Method; Treatment Outcome

2007

Other Studies

1 other study(ies) available for pregabalin and Cerebellar-Ataxia

Article	Year
Delayed onset of rotatory self-motion perception, dysdiadochokinesia and disturbed eye pursuit caused by low-dose pregabalin. BMJ case reports, 2014, Apr-11, Volume: 2014 A 30-year-old woman with chronic foot pain after an orthopaedic surgery and chronic neck pain presented to the emergency department (ED) with a history of self-rotatory vertigo with unsteadiness. She had started low-dose pregabalin, 25 mg two times a day 9 months before experiencing symptoms with the dose gradually increased to 150 mg two times a day over this period. Clinical examination revealed difficulty performing eye pursuit with left eye and dysdiadochokinesia of the left arm. Owing to a suspicion of multiple sclerosis she underwent cerebral MRI, which was normal. Pregabalin was tapered over 2 months with a complete disappearance of the symptoms. We concluded that symptoms were due to pregabalin treatment. Topics: Adult; Analgesics; Cerebellar Ataxia; Chronic Pain; Female; gamma-Aminobutyric Acid; Humans; Ocular Motility Disorders; Pregabalin; Vertigo	2014

Article

Year

Delayed onset of rotatory self-motion perception, dysdiadochokinesia and disturbed eye pursuit caused by low-dose pregabalin.

BMJ case reports, 2014, Apr-11, Volume: 2014

A 30-year-old woman with chronic foot pain after an orthopaedic surgery and chronic neck pain presented to the emergency department (ED) with a history of self-rotatory vertigo with unsteadiness. She had started low-dose pregabalin, 25 mg two times a day 9 months before experiencing symptoms with the dose gradually increased to 150 mg two times a day over this period. Clinical examination revealed difficulty performing eye pursuit with left eye and dysdiadochokinesia of the left arm. Owing to a suspicion of multiple sclerosis she underwent cerebral MRI, which was normal. Pregabalin was tapered over 2 months with a complete disappearance of the symptoms. We concluded that symptoms were due to pregabalin treatment.

Topics: Adult; Analgesics; Cerebellar Ataxia; Chronic Pain; Female; gamma-Aminobutyric Acid; Humans; Ocular Motility Disorders; Pregabalin; Vertigo

2014